UNSPSC 51172310: Folinic acid or leucovorin

This classification denotes a folic acid derivative with the molecular formula C20H23N7O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q573I9DVLP, chemically known as (+)-l-folinic acid, calcium salt but generally known as calcium folinate, which bears US NIH Compound Identifier 143. European Medicines Agency schedules Calcium folinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06052MIG.

The term LEUCOVORIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules calcium folinate in its Anatomical Therapeutic Chemical (ATC) Classification. Folinic acid or leucovorin bears US NLM identifiers UMLS ID C0023413 and NCI Concept Code C71631.

UNSPSC 51172310 Folinic acid or leucovorin, a Commodity-tier code, shows minimal alignment with actual state and local procurement activity. The three recent opportunities tagged under this code involve offender drug testing services, pharmaceutical benefit management infrastructure, and generic multi-source pharmaceutical distribution—none of which target folinic acid or leucovorin specifically. The Collin County Community Supervision and Corrections Department RFP solicits drug testing services including specimen collection, immunoassay screening, and confirmation testing under a $600,000 contract commencing September 1, 2026. The Texas Health and Human Services Commission RFI gathers market intelligence on direct-to-manufacturer prescription programs to bypass pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP establishes contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. These solicitations reflect state and local interest in pharmaceutical cost management and testing infrastructure, but do not name folinic acid or leucovorin as targeted products.

Opportunities are scattered across Texas (Collin County, HHS Commission), Minnesota (MMCAP), and subordinate jurisdictions within MMCAP's cooperative purchasing network. The issuing bodies span county corrections departments, state health agencies, and multi-state cooperative purchasing alliances. No recent solicitation explicitly names folinic acid or leucovorin procurement, and the code shows no concentrated activity pattern that would signal active demand. Collin County's RFP is due July 23, 2026, with award anticipated August 10, 2026. MMCAP's generic pharmaceutical RFP closed March 26, 2026. The Texas HHS RFI closed April 3, 2026 as a preliminary market-intelligence gathering effort with no formal award timeline specified. The mismatch between the code's nominal scope and the work actually being solicited suggests this code does not reliably describe current state and local procurement in pharmaceutical categories that would include folinic acid or leucovorin products.